Episode 94 - Cameron Turtle - CEO of Spyre Therapeutics

On this episode we welcomed Cameron Turtle, CEO of Spyre Therapeutics during the Jefferies Healthcare conference.

Spyre are developing next-generation antibodies, engineered for prolonged activity in the body and formulated for delivery as monotherapies or combination therapies to validated inflammatory targets. Their approach has the potential to deliver uncompromising efficacy and convenience for patients in a number of autoimmune indications.

This podcast was recorded in November 2025. Comments made during this podcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Spyre Therapeutic, Inc.'s (“Spyre”) expectations regarding Spyre’s product candidates including their potential safety and efficacy, business and clinical trial plans, milestones and timelines. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to Spyre's SEC filings, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q. These forward-looking statements are only as of the date they were made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.